Aditya Juloori UChicagoCancerCenter Thanks for the shoutout! One of the great things about training University of Chicago Radiation Oncology is working with cool data like this. Looking at our SBRT/ICI trial data we realized we had a kind of natural experiment going on (ICI w/ or w/o liver met SBRT).

More interesting findings from UChicago Chem and Rad Onc (Ralph Weichselbaum lab) on STING activation and the tumor microenvironment science.org/doi/full/10.11…

Could we hold off on checkpoint inhibitors in patients with low-volume metastatic disease and treat with local therapy instead? Our editorial exploring this idea: ascopubs.org/doi/10.1200/JC… (thanks to Ralph Weichselbaum Muzamil Arshad, MD/PhD Rohan Katipally Sean Pitroda, M.D.)

Considering negative trials of radiation and immunotherapy in light of available preclinical and translational data. Our review of this rapidly evolving field: sciencedirect.com/science/articl…

New Review in the August issue: Radiotherapy, immunity, and immune checkpoint inhibitors #radiotherapy #ImmuneCheckpointInhibitors thelancet.com/journals/lanon…